Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder
NCT ID: NCT00139594
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
181 participants
INTERVENTIONAL
2004-12-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
NCT00228059
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
NCT00238485
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00099229
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00107939
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
NCT00107926
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
licarbazepine
licarbazepine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
licarbazepine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* successful completion of study CLIC477D2303
* cooperation and willingness to comply with all study requirements
Exclusion Criteria
* failure to comply with study CLIC477D2303
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational site
La Palma, California, United States
Novartis Investigational Site
Kansas City, Kansas, United States
Novartis Investigational Site
Shreveport, Louisiana, United States
Novartis Investigational Site
Somerville, Massachusetts, United States
Novartis Investigational Site
Farmington Hills, Michigan, United States
Novartis Investigational Site
Staten Island, New York, United States
Novartis Investigational Site
Madison, Tennessee, United States
Novartis Investigational Site
Bellaire, Texas, United States
Novartis Investigational Site
Dallas, Texas, United States
Novartis Investigational Site
Verdun, Texas, United States
Novartis Investigational Site
Bellevue, Washington, United States
Novartis Investigational Site
Kirkland, Washington, United States
Novartis Investigational site
West Allis, Wisconsin, United States
Novartis Investigational Site
Vienna, , Austria
Novartis Investigational Site
Greater Sudbury, , Canada
Novartis Investigational Site
Kelowna, , Canada
Novartis Investigational Site
London, , Canada
Novartis Investigational Site
Montreal, , Canada
Novartis Investigator Site
Vancouver, , Canada
Novartis Investigational Site
Bogotá, , Colombia
Novartis Investigational Site
Medellín, , Colombia
Novartis Investigational Site
Pareira, , Colombia
Novartis Investigational Site
Brno, , Czechia
Novartis Investigational Site
Hradec Králové, , Czechia
Novartis Investigational Site
Prague, , Czechia
Novartis Investigational Site
Berlin, , Germany
Novartis Investigational Site
Bochum, , Germany
Novartis Investigational Site
Dresden, , Germany
Novartis Investigational Site
Ingolstadt, , Germany
Novartis Investigational Site
Mannheim, , Germany
Novartis Investigational Site
Würzburg, , Germany
Novartis Investigational Site
Guatemala City, , Guatemala
Novartis Investigational Site
Lima, , Peru
Novartis Investigational Site
Moscow, , Russia
Novartis Investigational Site
Yaroslavl, , Russia
Novartis Investigational Site
Bojnice, , Slovakia
Novartis Investigational Site
Michalovce, , Slovakia
Novartis Investigational Site
Durban, , South Africa
Novartis Investigational Site
Dnipro, , Ukraine
Novartis Investigational Site
Kiev, , Ukraine
Novartis Investigational Site
Luhansk, , Ukraine
Novartis Investigational Site
Odesa, , Ukraine
Novartis Investigational Site
Simferopol, , Ukraine
Novartis Investigational Site
Caracas, , Venezuela
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIC477D2303E1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.